FiercePharma

Quest Diagnostics to offer newly approved PD-L1 IHC 28-8 pharmDx test for non-squamous non-small cell carcinoma

MADISON, N.J., Oct. 9, 2015 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it now provides clinical laboratory ...
Nasdaq

Roche's VENTANA PD-L1 (SP142) Assay approved as first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq in ...

F. Hoffmann-La Roche Ltd / Roche's VENTANA PD-L1 (SP142) Assay approved as first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq in ...
Healio

High concordance observed among PD-L1 expression diagnostic assays

Please provide your email address to receive an email when new articles are posted on . NEW ORLEANS — Three commercially available diagnostic tests demonstrated similar efficacy when measuring PD-L1 ...
ascopubs.org

Analytical Concordance of PD-L1 Assays Utilizing Antibodies From FDA-Approved Diagnostics in Advanced Cancers: A Systematic Literature Review

PARP Inhibition in Prostate Cancer With Homologous Recombination Repair Alterations Literature searches were conducted in MEDLINE (via PubMed) and EMBASE to identify studies published between January ...
Business Wire

Agilent Technologies Receives Expanded FDA Approval for Use of Dako PD-L1 IHC 22C3 pharmDx Companion Diagnostic in Non-Small Cell Lung Cancer (NSCLC)

CARPINTERIA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that its Dako PD-L1 IHC 22C3 pharmDx now has an expanded label approved by the U.S. Food and Drug ...
Nature

PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability

In the clinical studies, various antibodies for immunohistochemical staining for PD-L1 have been used for the different drugs; clone 28-8 for nivolumab, 22C3 for pembrolizumab, SP142 for atezolizumab ...